TELO (Telomir Pharmaceuticals) EBIT per Share : $-0.61 (TTM As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Telomir Pharmaceuticals EBIT per Share?

Telomir Pharmaceuticals's EBIT per Share for the three months ended in Sep. 2024 was $-0.20. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.61.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Telomir Pharmaceuticals's EBIT per Share or its related term are showing as below:

TELO's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 2.8
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Telomir Pharmaceuticals's EBIT for the three months ended in Sep. 2024 was $-5.99 Mil.

Telomir Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Telomir Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telomir Pharmaceuticals EBIT per Share Chart

Telomir Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

EBIT per Share

-0.01

-0.03

-0.39

Telomir Pharmaceuticals Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial						-0.03	-0.29	-0.07	-0.05	-0.20

Telomir Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Telomir Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-11.429	/	29.610
=	-0.39

Telomir Pharmaceuticals's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-5.991	/	29.610
=	-0.20

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.61

Telomir Pharmaceuticals (NAS:TELO) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Telomir Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Telomir Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Telomir Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

855 N Wolfe Street, Suite 601, Baltimore, MD, USA, 21205

Website

https://www.telomirpharma.com

Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company leading the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.